CorMedix Inc (NASDAQ:CRMD) Receives $14.86 Average Price Target from Analysts

CorMedix Inc (NASDAQ:CRMD) has been given a consensus rating of “Moderate Buy” by the eight ratings firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $15.00.

A number of equities research analysts have weighed in on the company. Citizens Jmp restated a “market outperform” rating and issued a $19.00 target price on shares of CorMedix in a research report on Tuesday, April 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of CorMedix in a research report on Tuesday, August 11th. Royal Bank Of Canada boosted their price objective on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday. Needham & Company LLC upped their price objective on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, April 27th. Finally, Zacks Research raised CorMedix from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th.

CorMedix News Roundup

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Q2 results exceeded expectations: CorMedix reported earnings of $0.29 per share versus the $0.28 consensus estimate and revenue of $101.9 million, ahead of expectations near $96.0 million. Net income was $26.0 million and adjusted EBITDA was $58.7 million. CorMedix Second-Quarter Results
• Positive Sentiment: DefenCath and Melinta drove growth: Management cited solid DefenCath utilization and contributions from the Melinta portfolio as key factors behind the revenue beat, supporting the company’s commercial growth story. CRMD Q2 Earnings and Sales Beat
• Positive Sentiment: Profitability outlook improved: CorMedix maintained its fiscal 2026 revenue guidance of $325 million to $345 million, approximately in line with the $334.7 million analyst consensus, while raising its adjusted EBITDA guidance. The company also expects a supplemental filing for its fungal disease treatment by the third quarter, adding a potential pipeline catalyst. CorMedix Supplemental Filing Outlook
• Positive Sentiment: Analyst support strengthened: Royal Bank of Canada raised its price target from $13 to $14 and assigned an “outperform” rating. Other brokerages collectively maintain a “moderate buy” recommendation. RBC Price Target Update
• Neutral Sentiment: Guidance remains broadly aligned with expectations: Although the revenue outlook was maintained rather than raised, the higher EBITDA guidance indicates improving operating leverage and margins. Investors will likely focus on DefenCath adoption and execution against the second-half forecast.

CorMedix Stock Performance

Shares of NASDAQ:CRMD opened at $7.54 on Friday. The company has a 50 day moving average of $8.14 and a 200-day moving average of $7.65. The firm has a market cap of $587.67 million, a P/E ratio of 3.52 and a beta of 1.50. CorMedix has a twelve month low of $6.13 and a twelve month high of $14.96. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.05. CorMedix had a net margin of 40.49% and a return on equity of 40.52%. The business had revenue of $101.93 million during the quarter, compared to analysts’ expectations of $96.04 million. As a group, analysts anticipate that CorMedix will post 0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CorMedix

A number of institutional investors and hedge funds have recently bought and sold shares of CRMD. BlackRock Inc. bought a new position in shares of CorMedix during the 2nd quarter valued at about $49,644,000. Deerfield Management Company L.P. bought a new stake in shares of CorMedix in the 3rd quarter worth approximately $38,656,000. Marshall Wace LLP raised its holdings in shares of CorMedix by 34.6% in the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock worth $40,397,000 after purchasing an additional 893,518 shares in the last quarter. UBS Group AG lifted its stake in CorMedix by 295.3% during the third quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock valued at $12,687,000 after purchasing an additional 814,964 shares during the last quarter. Finally, Jump Financial LLC acquired a new stake in CorMedix during the third quarter valued at approximately $9,003,000. 34.18% of the stock is owned by institutional investors and hedge funds.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.